Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.39 |
| ▸ | WNT1 | P04628 | 4/20 | 0.35 |
| ▸ | GSK3B | P49841 | 4/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.35 |
| ▸ | CLK2 | P49760 | 2/20 | 0.35 |
| ▸ | CLK3 | P49761 | 2/20 | 0.35 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.33 |
| ▸ | MELK | Q14680 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 6/20 | 0.32 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.32 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.32 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20162155 | 0.93 | TAS2R8 (0.40) | TAS2R8WNT1GSK3BDYRK1ACLK2 | |
| SCHEMBL20162175 | 0.91 | TAS2R8 (0.39) | TAS2R8WNT1GSK3BDYRK1ACLK2 | |
| SCHEMBL20162162 | 0.89 | TAS2R8 (0.38) | TAS2R8WNT1GSK3BDYRK1ACLK2 | |
| SCHEMBL20162143 | 0.89 | TAS2R8 (0.37) | TAS2R8WNT1GSK3BDYRK1ACLK2 | |
| SCHEMBL20162176 | 0.87 | TAS2R8 (0.40) | TAS2R8WNT1GSK3BDYRK1ACLK2 | |
| SCHEMBL20162174 | 0.87 | HTR2C (0.43) | TAS2R8WNT1GSK3BDYRK1ACLK2 | |
| SCHEMBL20162120 | 0.86 | TAS2R8 (0.49) | TAS2R8WNT1GSK3BDYRK1ACLK2 | |
| SCHEMBL20162126 | 0.86 | RIPK1 (0.39) | TAS2R8RIPK1 | |
| SCHEMBL20162150 | 0.85 | HTR2C (0.46) | TAS2R8RIPK1 | |
| SCHEMBL20364394 | 0.84 | MAP3K5 (0.44) | TAS2R8WNT1GSK3BDYRK1ACLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200268728-A1 | DRUG TARGETING CANCER STEM CELL | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-08-27 | — | — | US | claimed |
| EP-3560494-A1 | DRUG TARGETING CANCER STEM CELL | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2019-10-30 | — | — | EP | claimed |
| US-10294237-B2 | Bicyclic heterocyclic amide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-05-21 | — | — | US | claimed |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-07-12 | — | — | US | claimed |
| EP-3323809-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2018-05-23 | — | — | EP | claimed |
| US-11434472-B2 | Agent for removing undifferentiated iPS cells | Sumitomo Pharma Co., Ltd. (JP) | 2022-09-06 | — | — | US | disclosed |
| US-20200268728-A1 | DRUG TARGETING CANCER STEM CELL | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-08-27 | — | — | US | disclosed |
| US-20200268728-A1 | DRUG TARGETING CANCER STEM CELL | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-08-27 | — | — | US | disclosed |
| EP-3560494-A1 | DRUG TARGETING CANCER STEM CELL | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2019-10-30 | — | — | EP | disclosed |
| EP-3560494-A1 | DRUG TARGETING CANCER STEM CELL | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2019-10-30 | — | — | EP | disclosed |
| US-10294237-B2 | Bicyclic heterocyclic amide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-05-21 | — | — | US | disclosed |
| US-10294237-B2 | Bicyclic heterocyclic amide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-05-21 | — | — | US | disclosed |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-07-12 | — | — | US | disclosed |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-07-12 | — | — | US | disclosed |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-07-12 | — | — | US | disclosed |
| WO-2018117196-A1 | DRUG TARGETING CANCER STEM CELL | 大日本住友製薬株式会社 | 2018-06-28 | — | — | WO | disclosed |
| EP-3323809-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2018-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10294237-B2 | Bicyclic heterocyclic amide derivative | NR0B1, NR2E1, NR0B2 | TAS2R8 2479/4885WNT1 223/4885GSK3B 3570/4885 |
| US-11434472-B2 | Agent for removing undifferentiated iPS cells | SALL4, NR4A2, NES | TAS2R8 2868/4885WNT1 302/4885GSK3B 2967/4885 |
| US-20200268728-A1 | DRUG TARGETING CANCER STEM CELL | NR5A1, NR3C1, NR3C2 | TAS2R8 2778/4885WNT1 704/4885GSK3B 3425/4885 |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | NR0B1, NR2E1, NR0B2 | TAS2R8 2479/4885WNT1 223/4885GSK3B 3570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.